Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Department of Pathology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Thorac Cancer. 2019 Sep;10(9):1841-1845. doi: 10.1111/1759-7714.13156. Epub 2019 Jul 27.
Adjuvant chemotherapy has long been indicated to extend survival in completely resected stage IB to IIIA non-small cell lung cancer (NSCLC). However, there is accumulating evidence that chemotherapy or chemoradiotherapy can induce epithelial-to-mesenchymal transition (EMT) in disseminated or circulating NSCLC cells. Here, we describe the first case of EMT as the cause of recurrence and metastasis in a patient with resected stage IIB lung adenosquamous carcinoma after adjuvant chemotherapy. We review the literature and explore the possible mechanisms by which EMT occurs in disseminated tumor cells (DTC) or circulating tumor cells (CTC) in response to adjuvant chemotherapy (cisplatin) as a stressor. We also explore the possible therapeutic strategies to reverse EMT in patients with recurrence. In summary, although adjuvant cisplatin-based chemotherapy in resected NSCLC does extend survival, it may lead to the adverse phenomenon of EMT in disseminated tumor cells (DTC) or circulating tumor cells (CTC) causing recurrence and metastasis.
辅助化疗长期以来被认为可以延长完全切除的 IB 期至 IIIA 期非小细胞肺癌(NSCLC)的生存期。然而,越来越多的证据表明,化疗或放化疗可以诱导播散或循环 NSCLC 细胞中的上皮-间充质转化(EMT)。在这里,我们描述了首例 EMT 作为辅助化疗后 IIB 期肺腺鳞癌患者复发和转移的原因。我们回顾了文献,并探讨了 EMT 在播散性肿瘤细胞(DTC)或循环肿瘤细胞(CTC)中发生的可能机制,以应对辅助化疗(顺铂)作为应激源。我们还探讨了逆转复发患者 EMT 的可能治疗策略。总之,尽管辅助顺铂为基础的化疗在切除的 NSCLC 中确实可以延长生存,但它可能导致 EMT 在播散性肿瘤细胞(DTC)或循环肿瘤细胞(CTC)中出现不良现象,从而导致复发和转移。